Active	Status	Sponsor type	Region	Phase	Filter
10 Active 1 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hassel, Jessica
Pivotal, NCT02938299 / 2015-002549-72: Neoadjuvant L19IL2/L19TNF- Study	Active, not recruiting	3	214	Europe	L19IL2 + L19TNF, Surgery	Philogen S.p.A.	Malignant Melanoma	10/24	12/28
ATOM, NCT06246149: Adjuvant Tebentafusp in High Risk Ocular Melanoma	Recruiting	3	290	Europe	Tebentafusp	European Organisation for Research and Treatment of Cancer - EORTC, Northwell Health, Immunocore Ltd	Uveal Melanoma	11/32	11/32
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)	Active, not recruiting	3	407	Europe, US, RoW	IO102-IO103, Pembrolizumab	IO Biotech, Syneos Health, Merck Sharp & Dohme LLC	Metastatic Melanoma, Unresectable Melanoma	07/25	09/27
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma	Recruiting	3	680	Europe, US, RoW	Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG	Immunocore Ltd	Advanced Melanoma	10/27	10/27
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Recruiting	2/3	420	Europe, Canada, US, RoW	IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome	IDEAYA Biosciences	Metastatic Uveal Melanoma	01/27	01/28
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma	Active, not recruiting	2	220	Europe, US, RoW	Botensilimab, AGEN1181, Balstilimab, AGEN2034	Agenus Inc.	Advanced Melanoma	05/28	05/28
DUNCAN, NCT04362722 / 2020-003299-42: Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients	Recruiting	2	40	Europe	L19IL2 +L19TNF, bifikafusp alfa + onfekafusp alfa	Philogen S.p.A., Philogen S.p.A.	Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell	09/24	09/24
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers	Active, not recruiting	2	77	Europe, Canada, US	SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin	Seagen Inc., Merck Sharp & Dohme LLC	Melanoma, Carcinoma, Non-Small- Cell Lung	01/24	10/25
DODEKA, NCT04471987: Safety and Early Signs of Efficacy of IL12-L19L19.	Recruiting	1	94	Europe	IL12-L19L19, Dodekin	Philogen S.p.A.	Advanced Solid Tumor, Metastatic Solid Tumor	12/25	12/25